Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP46A1 | Q9Y6A2 | 8/20 | 0.65 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.65 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.65 |
| ▸ | PGR | P06401 | 1/20 | 0.65 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | CNR1 | P21554 | 1/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.65 |
| ▸ | HTR2A | P28223 | 1/20 | 0.65 |
| ▸ | HTR2C | P28335 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.65 |
| ▸ | CCKBR | P32239 | 1/20 | 0.65 |
| ▸ | PPARG | P37231 | 1/20 | 0.65 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.65 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.65 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.65 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1152662 | 0.92 | PGR (0.55) | CYP46A1NR1I2NR3C1PGRADRB1 | |
| SCHEMBL8083795 | 0.84 | CYP46A1 (0.61) | CYP46A1NR1I2NR3C1PGRADRB1 | |
| SCHEMBL7661111 | 0.83 | PGR (0.48) | CYP46A1NR1I2NR3C1PGRADRB1 | |
| SCHEMBL7954675 | 0.83 | CYP46A1 (0.62) | CYP46A1NR1I2NR3C1PGRADRB1 | |
| SCHEMBL8075473 | 0.80 | CYP46A1 (0.67) | CYP46A1NR1I2NR3C1PGRADRB1 | |
| SCHEMBL14002297 | 0.80 | CYP46A1 (0.67) | CYP46A1NR1I2NR3C1PGRADRB1 | |
| SCHEMBL14439949 | 0.80 | CYP46A1 (0.76) | CYP46A1NR1I2NR3C1PGRADRB1 | |
| SCHEMBL16160982 | 0.79 | CYP46A1 (0.60) | CYP46A1NR1I2NR3C1PGRADRB1 | |
| Efavirenz SCHEMBL3227745 | 0.79 | CYP46A1 (1.00) | CYP46A1NR1I2NR3C1PGRADRB1 | |
| Efavirenz SCHEMBL464769 | 0.79 | CYP46A1 (1.00) | CYP46A1NR1I2NR3C1PGRADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0582455-B1 | Benzoxazinones as inhibitors of HIV reverse transcriptase | MERCK & CO INC (US) | 2000-11-02 | — | — | EP | claimed |
| US-5663169-A | Benzoxazinones as inhibitors of HIV reverse transcriptase | MERCK & CO., INC. (US) | 1997-09-02 | — | — | US | claimed |
| WO-1995020389-A1 | BENZOXAZINONES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | MERCK & CO., INC. (US) | 1995-08-03 | — | — | WO | claimed |
| WO-1994003440-A1 | BENZOXAZINONES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | MERCK & CO., INC. (US) | 1994-02-17 | — | — | WO | claimed |
| EP-0582455-A1 | Benzoxazinones as inhibitors of HIV reverse transcriptase | MERCK & CO. INC. (US) | 1994-02-09 | — | — | EP | claimed |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2013-10-31 | — | — | US | disclosed |
| US-8475804-B2 | Compositions and methods for treatment of filovirus-mediated diseases | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2013-07-02 | — | — | US | disclosed |
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | ZALICUS INC. | 2011-02-03 | — | — | US | disclosed |
| EP-0582455-B1 | Benzoxazinones as inhibitors of HIV reverse transcriptase | MERCK & CO INC (US) | 2000-11-02 | — | — | EP | disclosed |
| US-5811423-A | Benzoxazinones as inhibitors of HIV reverse transcriptase | MERCK & CO., INC. (US) | 1998-09-22 | — | — | US | disclosed |
| US-5665720-A | MIXTURE WITH NUCLEOSIDE ANALOG | MERCK & CO., INC. (US) | 1997-09-09 | — | — | US | disclosed |
| US-5663169-A | Benzoxazinones as inhibitors of HIV reverse transcriptase | MERCK & CO., INC. (US) | 1997-09-02 | — | — | US | disclosed |
| US-5519021-A | Benzoxazinones as inhibitors of HIV reverse transcriptase | MERCK & CO., INC. (US) | 1996-05-21 | — | — | US | disclosed |
| WO-1995020389-A1 | BENZOXAZINONES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | MERCK & CO., INC. (US) | 1995-08-03 | — | — | WO | disclosed |
| WO-1994003440-A1 | BENZOXAZINONES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | MERCK & CO., INC. (US) | 1994-02-17 | — | — | WO | disclosed |
| EP-0582455-A1 | Benzoxazinones as inhibitors of HIV reverse transcriptase | MERCK & CO. INC. (US) | 1994-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | CYP46A1 1649/4885NR1I2 4028/4885NR3C1 1352/4885 |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | CYP46A1 1649/4885NR1I2 4028/4885NR3C1 1352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.